Yanli Yang

Title: Yanli Yang: Innovator in Antibody Technology

Introduction

Yanli Yang is a prominent inventor based in South San Francisco, CA (US). She has made significant contributions to the field of antibody technology, holding 2 patents that showcase her innovative work. Her research focuses on developing multivalent and multiepitopic antibodies with agonistic activity, which have important applications in therapeutic settings.

Latest Patents

Yanli Yang's latest patents include groundbreaking advancements in antibody technology. The first patent, titled "Multivalent and multiepitopic antibodies having agonistic activity and methods of use," describes tetravalent antigen binding complexes that exhibit agonist activity for cell surface receptors. These complexes are designed to bind to multiple epitopes of the same receptor, enhancing their therapeutic potential. The second patent, "Antigen binding complex having agonistic activity and methods of use," details antigen binding polypeptides and their complexes that also demonstrate agonist activity. This patent includes methods for screening and enhancing the agonist activity of these polypeptides, further advancing the field.

Career Highlights

Throughout her career, Yanli Yang has worked with leading companies in the biotechnology sector. She has been associated with Genentech, Inc. and F. Hoffmann-La Roche AG, where she has contributed to various innovative projects. Her work has not only advanced scientific understanding but has also led to practical applications in medicine.

Collaborations

Yanli Yang has collaborated with notable professionals in her field, including Jeong Kim and Greg Lazar. These collaborations have fostered a productive environment for innovation and have contributed to the success of her research endeavors.

Conclusion

Yanli Yang is a distinguished inventor whose work in antibody technology has the potential to transform therapeutic approaches. Her patents reflect her commitment to advancing science and improving healthcare outcomes.